Market Research Industry Reports

Trillium Therapeutics Inc (TRIL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The companys lead program, TTI-621, a SIRPaFc fusion protein is being developed for hematological malignancies. Its second SIRPaFc fusion protein, TTI-622, is primarily being developed for combination therapy. Trillium has developed a proprietary medicinal chemistry platform that is used for the creation of new chemical entities with improved pharmacological properties from validated drugs and drug candidates. The company utilizing this platform is also developing bromodomain inhibitor and epidermal growth factor receptor antagonist. Trillium is headquartered in Mississauga, Ontario, Canada.

Trillium Therapeutics Inc (TRIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Fluorinov Pharma Raises US$1.5 Million In Venture Financing 12
Merger 13
Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13
Licensing Agreements 14
Trillium Therapeutics Amends Licensing Agreement with University Health Network 14
Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16
StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21
StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22
Equity Offering 23
Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23
Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24
Trillium Therapeutics Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25
Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27
Stem Cell Therapeutics Completes Private Placement Of Shares For US$31 Million 28
Stem Cell Therapeutics Completes Public Offering Of Units For US$3.2 Million 30
Acquisition 31
Trillium Therapeutics Acquires Fluorinov Pharma 31
Trillium Therapeutics Inc - Key Competitors 32
Trillium Therapeutics Inc - Key Employees 33
Trillium Therapeutics Inc - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 11, 2018: Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results 35
Mar 09, 2018: Trillium Therapeutics Reports Annual 2017 Financial And Operating Results 36
Nov 10, 2017: Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results 37
Aug 11, 2017: Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results 38
May 12, 2017: Trillium Reports First Quarter 2017 Financial and Operating Results 39
Mar 10, 2017: Trillium Therapeutics Reports Annual 2016 Financial and Operating Results 40
Corporate Communications 41
Jun 07, 2018: Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer 41
Product News 42
04/10/2018: Trillium Therapeutics Provides Update on TTI-622 Program 42
Clinical Trials 43
Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List Of Tables

List of Tables
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fluorinov Pharma Raises US$1.5 Million In Venture Financing 12
Stem Cell Therapeutics Completes Merger With Trillium Therapeutics 13
Trillium Therapeutics Amends Licensing Agreement with University Health Network 14
Stem Cell Therapeutics Enters Into Licensing Agreement With MaRS Innovation For Cancer Stem Cell Program 16
StemCell Technologies Enters Into Licensing Agreement With HUB Foundation for Organoid Technology 18
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University Of Toronto 19
Stem Cell Therapeutics Enters Into Option For Licensing Agreement With University of York For Prostate Cancer Stem Cell Assets 21
StemCell Technologies Enters Into Licensing Agreement With iPS Academia Japan For Induced Pluripotent Stem Cell Technologies 22
Trillium Therapeutics Files Shelf Prospectus to Raise up to USD150 Million 23
Trillium Therapeutics Raises USD20 Million in Private Placement of Shares 24
Trillium Therapeutics Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares and Prefererd Shares for USD31 Million 25
Trillium Therapeutics Raises USD55.2 Million in Public Offering of Shares 27
Stem Cell Therapeutics Completes Private Placement Of Shares For US$31 Million 28
Stem Cell Therapeutics Completes Public Offering Of Units For US$3.2 Million 30
Trillium Therapeutics Acquires Fluorinov Pharma 31
Trillium Therapeutics Inc, Key Competitors 32
Trillium Therapeutics Inc, Key Employees 33
Trillium Therapeutics Inc, Subsidiaries 34

List Of Figures

List of Figures
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trillium Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trillium Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Trillium Therapeutics Inc (TRIL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The companys lead program, TTI-621, a SIRPaFc

USD 250View Report

Trillium Therapeutics Inc (TRIL) - Financial and Strategic SWOT Analysis Review

Trillium Therapeutics Inc (TRIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125View Report

Endonovo Therapeutics Inc (ENDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The companys products include Electroceutical Therapy a FDA-Cleared for the palliative treatment

USD 250View Report

Pear Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD)

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :44
Country :Canada
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube